This technique uses local anesthetic blocks in conjunction with electric cell signaling treatment (EST) to successfully treat neuropathies of all causes.
Robert H. Odell, Jr., MD, PhD, Richard Sorgnard, PhD, Peter Carney, MD, Robert Milne, MD
A neuropathy occurs as a result of basic patho- logic processes gone awry—either from injury or disease. The incidence of neu- ropathy increases with age and its preva- lence is growing. In fact, the prevalence of peripheral neuropathy may be as high as 2.4% in the United States.1 A study of
people with diabetes estimated the prevalence of diabetic peripheral neuropathy (DPN) in patients with type 2 dia- betes to be 26.4%.2 DPN is often the first indication to the patient that they have diabetes.3 Morbidity associated with diabetic and other neuropathies is a major reason patients seek medical care and represents a major cost to patients and society.4,5
It is compelling to note that the course of DPN, as well as other neuropathies, generally is progressive. To date, most
treatments have focused on reduction of symptoms,6 and, in the case of diabetes, control or slowing of the progres- sion of the underlying disease.
Combined electrochemical treatment (CET) represents a safe and effective therapy for all forms of neuropathy.7 We have now documented the reversal of the neuropathic process both from clinical observations and from objective functional (neurodiagnostic) testing and anatomic (epidural nerve fiber density [ENFD]) data.8 Although our clinics have not yet initialized formal double-blinded control studies, our clinical outcomes strongly suggest that the CET proto- col is making a substantive difference in patients’ lives and certainly warrants more detailed consideration.
This paper will discuss neuropathic pathophysiology, with a focus on DPN. We will discuss how biochemistry and physics act in concert for healing.